Literature DB >> 26723850

[Post-menopausal osteoporosis: Up-to-date].

K Briot1, C Roux2.   

Abstract

Patients with a high risk of fragility fractures, and those with recent fractures, must receive the highest priority for anti-osteoporotic treatment, because of the consequences of some of these fractures (hip, vertebrae, pelvis, humerus). Both non pharmacological and pharmacological treatments must be used. The duration of the treatment is based on the assessment of fracture risk.
Copyright © 2015 Société nationale française de médecine interne (SNFMI). Published by Elsevier SAS. All rights reserved.

Entities:  

Keywords:  Anti-osteoporotic treatment; Fracture; Ostéoporose post-ménopausique; Post-menopausal osteoporosis; Traitement anti-ostéoporotique

Mesh:

Substances:

Year:  2015        PMID: 26723850     DOI: 10.1016/j.revmed.2015.11.008

Source DB:  PubMed          Journal:  Rev Med Interne        ISSN: 0248-8663            Impact factor:   0.728


  1 in total

1.  Expansion of Bone Precursors through Jun as a Novel Treatment for Osteoporosis-Associated Fractures.

Authors:  Tristan Lerbs; Lu Cui; Claire Muscat; Atif Saleem; Camille van Neste; Pablo Domizi; Charles Chan; Gerlinde Wernig
Journal:  Stem Cell Reports       Date:  2020-03-19       Impact factor: 7.765

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.